HYFT

#4171
MindWalk Holdings Corp. - Common Stock
1.3 0 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.30
1.30
Intervallo Annuale
0.99
2.95
Variazione giornaliera
-2.99%
Variazione Mensile
+0.78%
Variazione di 6 mesi
+15.04%
Variazione Annuale
-35.64%
Chiusura Precedente
1.3 4
Open
1.3 0
Minimo
1.3 0
Massimo
1.3 0
Volume
4
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Mindwalk Holdings Corp. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
Mindwalk Holdings Corp. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
Mindwalk Holdings Corp. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
Mindwalk Holdings Corp. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
Mindwalk Holdings Corp. current report, Q3 FY2026
6-K
Current report, Q2 FY2026
Mindwalk Holdings Corp. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Mindwalk Holdings Corp. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Mindwalk Holdings Corp. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Mindwalk Holdings Corp. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
Mindwalk Holdings Corp. current report, Q2 FY2026
6-K

Mindwalk Holdings Corp. current report, Q4 FY2024

Full document

Business Context and Reporting Period

Company: ImmunoPrecise Antibodies Ltd. (Note: Request metadata listed "Mindwalk Holdings Corp." but the filing text confirms the registrant is ImmunoPrecise Antibodies Ltd.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 23, 2024
Reporting Period: This filing serves as a Notice of Annual General Meeting (AGM) and Management Information Circular for the fiscal year ended April 30, 2024. The AGM is scheduled for November 14, 2024.

Key Financial Metrics

Note: This filing is a proxy statement and does not contain a full set of financial statements. Specific revenue, profit, and cash flow figures for the fiscal year ended April 30, 2024, are not provided in this text. Investors are directed to the Annual Information Form (AIF) and financial statements on SEDAR+.

  • Capital Structure: 28,832,251 Common Shares issued and outstanding as of October 14, 2024.
  • Share Price: U.S. $1.28 (Closing price on Nasdaq Global Market as of April 30, 2024).
  • Equity Compensation: 1,521,367 securities available for issuance under outstanding options; 1,173,083 securities remaining available for future issuance.
  • Executive Compensation (Fiscal 2024):
    • CEO (Dr. Jennifer L. Bath): Total compensation of CAD $1,005,342 (Salary: CAD $731,989; Incentive: CAD $273,353).
    • CFO (Kristin Taylor): Total compensation of CAD $533,477 (Salary only; no equity awards in 2024).
  • Auditor Fees: CAD $10,616 for executive compensation-related fees (Arnosti Consulting) for the year ended April 30, 2024.

Material Changes and Governance Updates

  • Board Composition Change: The Board currently has five members. Shareholders are asked to reduce the number of directors to four. Mr. Mitch Levine has opted not to stand for re-election.
  • Committee Restructuring: The Remuneration and Nomination Committee and the Governance Committee were merged on October 14, 2024, to form the "Remuneration, Nomination and Governance Committee."
  • Executive Leadership: Kristin Taylor was appointed permanent CFO on June 16, 2024, succeeding Brad McConn (who resigned in September 2023) and Lisa Helbling (who served as interim CFO).
  • Compensation Adjustments: Executive compensation was benchmarked against 24 peer companies. CEO Dr. Bath's compensation includes a guaranteed annual bonus of U.S. $200,000.

Outlook, Risks, and Contingencies

  • Change of Control Benefits: Significant severance provisions exist for the CEO. In the event of an "Involuntary Termination" following a Change of Control, Dr. Bath is entitled to 24 months of salary, twice the guaranteed bonus, and twice the discretionary bonus (estimated total of CAD $2,722,090 as of April 30, 2024).
  • Compensation Risks: The Remuneration Committee has not identified risks associated with the compensation program that would likely have a material adverse effect on the Company.
  • Financial Outlook: The filing does not provide specific revenue guidance or operational outlook for the upcoming fiscal year. It notes that the Company is a "junior pharmaceutical and life sciences issuer" with limited financial resources, which influences its compensation strategy (not tying compensation to performance criteria).
  • Contingencies: The Audit Committee is responsible for reviewing litigation, claims, or other contingencies that could materially affect financial position, but no specific pending litigation is detailed in this text.

Investor Verification Checklist

  • Verify Financials: Retrieve the full audited financial statements for the year ended April 30, 2024, from SEDAR+ or the company website, as this filing only references them.
  • Board Election: Confirm the outcome of the vote to reduce the Board size to four and the election of the four proposed nominees (Dr. Bath, Chris Buyse, Dr. Barry Springer, Dirk Witters).
  • Shareholder Approval: Monitor the vote on the appointment of Grant Thornton LLP as the external auditor.
  • Equity Dilution: Review the total number of options outstanding (1.52 million) relative to the shares outstanding (28.8 million) to assess potential dilution.
  • Executive Retention: Review the specific terms of the Change of Control agreement for the CEO, noting the significant payout potential in a merger or acquisition scenario.